No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE

(2020) A Atkinson et al.   CLINICAL INFECTIOUS DISEASES

IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients

(2019) Agnieszka Wójtowicz et al.   AIDS

HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets

(2018) Alison E Brown et al.   Eurosurveillance

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies

(2017) Lukas Fenner et al.   Journal of the International AIDS Society

Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

(2016) Kate Buchacz et al.   JOURNAL OF INFECTIOUS DISEASES

Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count

(2015) Vaninder K. Sidhu et al.   ANNALS OF PHARMACOTHERAPY

Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis

(2015) Amitabh B Suthar et al.   Lancet HIV

Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-Infected Patients Who Had CD4+ Cell Count

(2013) Romanee Chaiwarith et al.   AIDS PATIENT CARE AND STDS

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

(2013) Amanda Mocroft et al.   PLOS MEDICINE

Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults

(2012) D.V. Potsch et al.   VACCINE

Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count

(2011) Cecilia T. Costiniuk et al.   PLoS One

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

(2010) Chien-Yu Cheng et al.   BMC INFECTIOUS DISEASES

Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count

(2010)   CLINICAL INFECTIOUS DISEASES

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

(2010) AS Walker et al.   LANCET

Randomized, Double‐Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients

(2009) John Evison et al.   CLINICAL INFECTIOUS DISEASES